Neurodegenerative diseases, such as Alzheimer’s disease, Parkinson’s disease, and frontotemporal dementia, are a growing health concern worldwide, and their diagnosis and management are still challenging. However, recent advances in blood-based biomarkers offer new opportunities for clinical evaluation and monitoring of these diseases.
In this review article, entitled “Blood Biomarkers in Neurodegenerative Diseases: Implications for the Clinical Neurologist“ and published in Neurology, researchers from Sant Pau Memory Unit, Daniel Alcolea and Alberto Lleó, together with authors from Mount Sinai (New York, USA), Sheba Medical Center Tel-Hashomer (Israel) and University of California San Francisco (San Francisco, USA) provide an overview of the current state of blood biomarkers for neurodegenerative diseases and their potential implications for clinical neurologists.
Blood-based biomarkers
The authors discuss the different types of blood biomarkers that have been studied, including those related to amyloid and tau pathologies specific to Alzheimer’s disease, as well as non-specific markers of neuronal and glial degeneration that can be found in several neurodegenerative diseases.
Specifically, the authors highlight the robustness of assays for Aß peptides and p-tau in Alzheimer’s disease. These markers have been shown to correlate with the degree of cognitive impairment in Alzheimer’s disease and are being studied for screening, diagnosis, and treatment response monitoring. In addition to disease-specific markers, the authors discuss non-specific markers of neurodegeneration, including neurofilament light, ß-synuclein, and ubiquitin-C-terminal-hydrolase-L1. These markers have been shown to be elevated in several neurodegenerative diseases, and their levels correlate with disease severity and progression.
The research group of the Sant Pau Memory Unit has led numerous works focused on the research line of blood-based markers.
Potential of blood-based biomarkers
The authors highlight the potential of blood-based biomarkers to be used in different clinical settings, such as primary care, memory clinics, and research centers and discuss the advantages of using blood biomarkers over other diagnostic methods, such as imaging or cerebrospinal fluid analysis, including lower cost, less invasive procedures, and wider availability.
Overall, this review article provides a comprehensive overview of the current state of blood biomarkers for neurodegenerative diseases and their potential implications for clinical neurologists. While further research is needed to validate and standardize these markers for clinical use, the authors suggest that blood-based biomarkers offer a promising avenue for the diagnosis and management of neurodegenerative diseases in the near future.
This is a fascinating and timely review! The discussion on the potential of blood-based biomarkers to simplify and enhance the diagnosis of neurodegenerative diseases is incredibly promising. As a non-invasive and cost-effective alternative to traditional methods, these biomarkers could revolutionize access to early detection and personalized treatment plans. The mention of robust assays for Aß peptides and p-tau, particularly in Alzheimer’s, highlights how far the field has come. I’m curious about the challenges that still need to be overcome for these biomarkers to become standardized in clinical practice—are there specific hurdles related to variability or reliability across diverse populations? Thank you for shedding light on such an important topic!
Thank you for your thoughtful and encouraging feedback! We are glad you found the review engaging and timely. You’re absolutely right about the transformative potential of blood-based biomarkers in neurodegenerative diseases. They hold immense promise for improving early detection and accessibility.
Regarding your question about challenges, standardizing these biomarkers in clinical practice does face several hurdles. Variability across diverse populations is indeed a significant concern, as factors like genetic background, comorbidities, and even pre-analytical sample handling can influence biomarker levels. Additionally, ensuring assay reliability and sensitivity across different laboratories and platforms is crucial. Another key challenge is the need for longitudinal studies to establish how well these biomarkers correlate with disease progression in real-world scenarios.
For a deeper exploration of these challenges and the global benefits of using biomarkers for neurodegeneration in research and clinical care, we highly recommend *The Lancet’s* series on biomarkers of neurodegeneration. This collection of articles provides a comprehensive overview of the field, highlighting advances, limitations, and the path forward for integrating biomarkers into clinical practice. You can find it here: [The Lancet Series on Biomarkers of Neurodegeneration](https://www.thelancet.com/series/biomarkers-of-neurodegeneration).
Thank you again for your interest in this evolving field. It’s an exciting time for innovation in neurodegenerative research!